A robustness-based approach to systems-oriented drug design
The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index.
Abstract
Many potential drugs that specifically target a particular protein considered to underlie a given disease have been found to be less effective than hoped, or to cause significant side effects. The intrinsic robustness of living systems against various perturbations is a key factor that prevents such compounds from being successful. By studying complex network systems and reformulating control and communication theories that are well established in engineering, a theoretical foundation for a systems-oriented approach to more effectively control the robustness of living systems, particularly at the cellular level, could be developed. Here, I use examples that are based on existing drugs to illustrate the concept of robustness, and then discuss how a greater consideration of the importance of robustness could influence the design of new drugs that will be intended to control complex systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is commonly the case in complex biochemical networks that while changes in individual parameters have little effect on the behaviour of biochemical pathways—indeed evolution is thought to have selected for robustness to individual parameter changes”
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The Byzantine generals problem
Lamport, L., Shostak, R., & Pease, M. (1982) · ACM Transactions on Programming Languages and Systems · doi:10.1145/357172.357176 · Cited by 6,023 · cited 1×
“Fail-on failure (also known as Byzantine failure) has been a major problem for communication networks, and is considered to be a crucial problem in complex network systems in genera”
BackgroundDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“A further illustrative case is that of imatinib (Gleevec; Novartis), which is considered as a successful example of a drug that targets the protein product of a disease-causative gen”
BackgroundROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
“The relationship between kinetics and systemic responses to perturbations offers an intriguing additional dimension in which network pharmacology strategies can be applied; it also provides a framework for understanding systems response”
BackgroundWang, X., Shen, Y., Wang, S., Li, S., Zhang, W., Liu, X., Lai, L., Pei, J., & Li, H. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx374 · Cited by 1,588
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
“…to the simultaneous action of several drugs, provides new opportunities for the rational development of combination therapies (Smalley et al. 2006; Kitano 2007; Zimmermann et al. 2007; Podolsky and Greene 2011) and exploits the chances for better efficacy, decreased toxicity, and reduced…”
BackgroundMechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
“With such issues in mind, systems-oriented drug design has been increasingly emphasized as a potentially more productive strateg”
BackgroundSynergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
“This requires precise target modulation, which can be thwarted by the compensatory mechanisms available to complex biological system”
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
“…energies and thus destabilize malignant or infectious cells causing an ‘error catastrophe’ and activating cell death. e. Drugs may increase activation energies and thus stabilize healthy cells preventing their shift to the diseased phenotype (Csermely, 2004, 2009; Kitano, 2004a, 2004b, 2007).”
BackgroundInfluentialTowards a theory of biological robustness
Kitano, H. (2007) · Molecular Systems Biology · doi:10.1038/msb4100179 · Cited by 803
“Some diseases can be considered as manifestations of such trade-offs (Kitano et al, 2004; Kitano, 2004b; Kitano and Oda, 2006), and the efficacy and side effects of drugs may be related to robustness trade-offs (Kitano, 2007b).”
BackgroundSelf-citationSilver Enhances Antibiotic Activity Against Gram-Negative Bacteria
Morones-Ramirez, J. R., Winkler, J. A., Spina, C. S., & Collins, J. J. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006276 · Cited by 756
Phospho.ELM: a database of phosphorylation sites--update 2011
Dinkel, H., Chica, C., Via, A., Gould, C. M., Jensen, L. J., Gibson, T. J., & Diella, F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1104 · Cited by 740
Tang, J., Szwajda, A., Shakyawar, S., Xu, T., Hintsanen, P., Wennerberg, K., & Aittokallio, T. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400709d · Cited by 645
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis
Xue, R., Fang, Z., Zhang, M., Yi, Z., Wen, C., & Shi, T. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1100 · Cited by 617
Loscalzo, J., Kohane, I., & Barabasi, A. (2007) · Molecular Systems Biology · doi:10.1038/msb4100163 · Cited by 603
“…cancer; Ergun et al, 2007), to determine the appropriate dosing of a drug, based on metabolomic profiling (Nicholson, 2006), and to ascertain the causes of resistance to therapies or enhanced toxicities of drugs based on the robustness-fragility trade-off inherent in the system (Kitano, 2007).”
BackgroundKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Kibble, M., Saarinen, N., Tang, J., Wennerberg, K., Mäkelä, S., & Aittokallio, T. (2015) · Natural Product Reports · doi:10.1039/c5np00005j · Cited by 489
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…of bio- chemical pathways—indeed evolution is thought to have selected for robustness to individual parameter changes (Bornholdt and Sneppen 2000; Kitano 2007; Lehár et al. 2008; Morohashi et al. 2002; Stelling et al. 2004; Wagner 2005)—combinations of parameter changes can and do have major…”
BackgroundUnveiling the role of network and systems biology in drug discovery
Pujol, A., Mosca, R., Farrés, J., & Aloy, P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.006 · Cited by 346
Network biology concepts in complex disease comorbidities
Hu, J. X., Thomas, C. E., & Brunak, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.87 · Cited by 328
Wang, X., Pan, C., Gong, J., Liu, X., & Li, H. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00690 · Cited by 290
Feng, Y., Mitchison, T. J., Bender, A., Young, D. W., & Tallarico, J. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2876 · Cited by 279
“; our current understanding of how potential targets function at the system level is still poor, so perhaps it is inevitable that target-based approaches will often result in failur”
BackgroundLi, S., Zhang, B., Jiang, D., Wei, Y., & Zhang, N. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s11-s6 · Cited by 275
“TCM formula is considered to be an empirical system of multicomponent therapeutics which potentially meets the demands of treating a number of complex diseases in an integrated manner [3,14,15].”
BackgroundTrans-Omics: How To Reconstruct Biochemical Networks Across Multiple ‘Omic’ Layers
Yugi, K., Kubota, H., Hatano, A., & Kuroda, S. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.12.013 · Cited by 258
“Systems medicine aims to correct the behavior of a group of molecules by using pathway information [99,100], and is expected to change current reactive medicine, which is enacted after people contract disease, to predictive and personalized medicine based on genomic data [101–103].”
BackgroundA comprehensive map of the mTOR signaling network
Caron, E., Ghosh, S., Matsuoka, Y., Ashton‐Beaucage, D., Therrien, M., Lemieux, S., Perreault, C., Roux, P. P., & Kitano, H. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.108 · Cited by 241
“Indeed, properly designed multicomponent therapies are the first step in controlling robustness to achieve clinical efficacy (Kitano, 2007).”
BackgroundSelf-citationPROMISCUOUS: a database for network-based drug-repositioning
von Eichborn, J., Murgueitio, M. S., Dunkel, M., Koerner, S., Bourne, P. E., & Preissner, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1037 · Cited by 225
Combinatorial strategies for combating invasive fungal infections
Spitzer, M., Robbins, N., & Wright, G. D. (2017) · Virulence · doi:10.1080/21505594.2016.1196300 · Cited by 218
High-content single-cell drug screening with phosphospecific flow cytometry
Krutzik, P. O., Crane, J. M., Clutter, M. R., & Nolan, G. P. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.2007.59 · Cited by 207
“Generally, pathways that were induced less strongly (that is, that had lower fold induction of phosphorylation) were inhibited more selectively by all the compound”
BackgroundXie, L., Xie, L., Kinnings, S. L., & Bourne, P. E. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134630 · Cited by 202
Threatening cancer with nanoparticle aided combination oncotherapy
Rawal, S., & Patel, M. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.015 · Cited by 199
Pathway databases and tools for their exploitation: benefits, current limitations and challenges
Bauer‐Mehren, A., Furlong, L. I., & Sanz, F. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.47 · Cited by 193
“Moreover, systems can be subjected to functional disruptions when facing perturbations for which they are not optimized, thus showing points of fragility of the biological system (Kitano, 2007b).”
BackgroundInfluentialLi, X., Xu, X., Wang, J., Yu, H., Wang, X., Yang, H., Xu, H., Tang, S., Li, Y., Yang, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043918 · Cited by 189
“With the growing understanding of the complex disease, the focus of drug discovery has shifted from the well-accepted ‘‘one target, one drug’’ model designed toward a single target to a new ‘‘multi-target, multi-drug’’ model aimed at systemically modulating multiple targets in body [95].”
BackgroundDiseases as network perturbations
del Sol, A., Balling, R., Hood, L., & Galas, D. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.07.010 · Cited by 188
“Furthermore, considering complex diseases as robust systems exhibiting nevertheless points of fragility may provide insights for the development of new drugs [39].”
BackgroundFinding multiple target optimal intervention in disease‐related molecular network
Yang, K., Bai, H., Ouyang, Q., Lai, L., & Tang, C. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.60 · Cited by 186
“To overcome the limitations of the single-target-based drugs, growing attention has been paid to drug discoveries involving multiple targets and at the level of disease networks (Csermely et al , 2005; Frantz, 2005; Kitano, 2007; Zimmermann et al , 2007).”
BackgroundInfluentialHow to design multi-target drugs: target search options in cellular networks
Korcsmáros, T., Szalay, M. S., Böde, C., Kovács, I. A., & Csermely, P. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.6.799 · Cited by 155
“Moreover, many cellular networks are robust and prevent major changes in their outputs, despite dramatic changes in their constituents [12-15] .”
BackgroundCross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
“metabolism and detoxification, and genetic feedback between different network elements (Sharom et al, 2004; Kitano, 2007; Lehar et al, 2008).”
Computational Multitarget Drug Design
Zhang, W., Pei, J., & Lai, L. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00491 · Cited by 180
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Where is the hope for drug discovery? Let history tell the future
De, K., Li, X., & Zhang, H. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.07.002 · Cited by 179
Li, H., Zhao, L., Zhang, B., Jiang, Y., Wang, X., Guo, Y., Liu, H., Li, S., & Tong, X. (2014) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2014/495840 · Cited by 177
“Interestingly, the network-based therapeutic strategies are evidence based presumably in agreement with the properties of TCM herbal formulae [48].”
Tang, J., & Aittokallio, T. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990470 · Cited by 175
“The potential of drug target combinations is perhaps best appreciated in anticancer research, where both genetic and non-genetic bypass mechanisms have led to inherent redundancy and robustness of compensatory signaling pathways in many cancer phenotypes [3; 6].”
BackgroundInfluentialA network medicine approach to human disease
Zanzoni, A., Soler-López, M., & Aloy, P. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.03.001 · Cited by 171
“The efficacy of such therapies can be explained by the fact that drugs targeting different proteins in the disease network or pathway could trigger a more-than-additive effect, and that their combination can eliminate compensatory reactions, avoiding thus a drug-resistance denouement [80].”
BackgroundBiomolecular modeling and simulation: a field coming of age
Schlick, T., Collepardo‐Guevara, R., Halvorsen, L., Jung, S. C., & Xiao, X. (2011) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583510000284 · Cited by 171
Degeneracy: a link between evolvability, robustness and complexity in biological systems
Whitacre, J. M. (2010) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-7-6 · Cited by 170
“However, even if highly versatile components do exhibit a relatively low affinity in each of their interactions, they may still have a large influence on system coherence, integration, and stability [58,59].”
BackgroundKell, D. B., & Goodacre, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.014 · Cited by 169
“Nature 406, 188–192 147 Kitano, H. (2004) Biological robustness. Nat. Rev. Genet. 5, 826–837 148 Quinton-Tulloch, M.J. et al. (2013) Trade-off of dynamic fragility but not of robustness in metabolic pathways in silico.”
BackgroundInfluentialFunctionalized graphene oxide as a vehicle for targeted drug delivery and bioimaging applications
Karki, N., Tiwari, H., Tewari, C., Rana, A., Pandey, N., Basak, S., & Sahoo, N. G. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01149e · Cited by 169
Xie, L., Evangelidis, T., Xie, L., & Bourne, P. E. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002037 · Cited by 165
“Multiple node failures have been called ‘‘fail-on’’ [50], and used to explain neurological disorders [51] and cancer [52,53] in recent genome-wide studies.”
BackgroundStructure-based systems biology for analyzing off-target binding
Xie, L., Xie, L., & Bourne, P. E. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.004 · Cited by 163
“Simply stated, the disappointing outcome of current approaches to drug discovery emphasizes the need to assess and possibly employ a new polypharmacology paradigm [3,4].”
BackgroundEvidence of perturbations of the cytokine network in preterm labor
Romero, R. J., Grivel, J., Tarca, A. L., Chaemsaithong, P., Xu, Z., Fitzgerald, W., Hassan, S. S., Chaiworapongsa, T., & Margolis, L. B. (2015) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.07.037 · Cited by 162
Integrative genome‐scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery
Kim, H. U., Kim, S. Y., Jeong, H., Kim, T. Y., Kim, J. J., Choy, H. E., Yi, K. Y., Rhee, J. H., & Lee, S. Y. (2011) · Molecular Systems Biology · doi:10.1038/msb.2010.115 · Cited by 160
“As biological systems are optimized through evolution giving them robustness, targeting for antibacterial drugs can, in essence, be achieved by disrupting the robustness of the pathogen, and thereby effectively suppressing its growth (Kitano, 2007).”
Yu, K., Ganesan, K., Tan, L. K., Laban, M., Wu, J., Zhao, X. D., Li, H., Leung, C. H. W., Zhu, Y., Wei, C. L., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000129 · Cited by 159
“However, many complex systems have evolved to exhibit a ‘robust yet fragile’ structure [63,64], and it has been proposed that studying mechanisms of cancer-specific robustness and accompanying fragilities might prove useful for the development of novel targeted therapies [65–67].”
BackgroundDrug-Induced Regulation of Target Expression
Iskar, M., Campillos, M., Kuhn, M., Jensen, L. J., van Noort, V., & Bork, P. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000925 · Cited by 142
“Many drug targets thought to be suitable for therapeutic purposes turn out to be less effective than expected or account for adverse side effects [4].”
BackgroundNew Insights into Toxicity and Drug Testing
(2013) · InTech eBooks · doi:10.5772/55886 · Cited by 149
Meyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Metabolic profiling studies on the toxicological effects of realgar in rats by 1H NMR spectroscopy
Wei, L., Liao, P., Wu, H., Li, X., Pei, F., Li, W., & Wu, Y. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.11.010 · Cited by 143
“Metabonomics techniques are extremely suitable for probing the mechanisms and evaluate the safety of Chinese medicine (Nicholson andWilson, 2003; Kitano, 2007), and we have previously reported the biochemical effects of traditional Chinese medicine cinnabar (Wei et al.”
BackgroundMethodPrediction of Synergism from Chemical-Genetic Interactions by Machine Learning
Wildenhain, J., Spitzer, M., Dolma, S., Jarvik, N., White, R., Roy, M., Griffiths, E., Bellows, D. S., Wright, G. D., & Tyers, M. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.003 · Cited by 121
“Drug combinations can lead to increased clinical efficacy (Sharom et al., 2004; Kitano, 2007; Lehar et al., 2009) and prevent the emergence of resistance (Pisco et al., 2013; Crystal et al., 2014; Chen et al., 2015).”
InfluentialChen, J., Wang, Y., Gao, Y., Hu, L.-S., Yang, J.-W., Wang, J., Sun, W., Liang, Z., Cao, Y., & Cao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110281 · Cited by 131
From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy
Zheng, H., Fridkin, M., & Youdim, M. (2014) · Pharmaceuticals · doi:10.3390/ph7020113 · Cited by 120
“the robust phenotypes of biological systems [4].”
Structure of Protein Interaction Networks and Their Implications on Drug Design
Hase, T., Tanaka, H., Suzuki, Y., Nakagawa, S., & Kitano, H. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000550 · Cited by 108
“This is consistent with the idea of ‘‘long-tail drugs’’[19].”
Self-citationKell, D. B. (2013) · The FEBS Journal · doi:10.1111/febs.12268 · Cited by 121
“22 Kitano H (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6, 202–210. 23 Daniels BC, Chen YJ, Sethna JP, Gutenkunst RN & Myers CR (2008) Sloppiness, robustness, and evolvability in systems biology. Curr Opin Biotechnol 19, 389–395. 24 Leh ar J, Krueger A, Zimmermann G & Borisy…”
BackgroundMethodInfluentialToxicological effects of cinnabar in rats by NMR-based metabolic profiling of urine and serum
Wei, L., Liao, P., Wu, H., Li, X., Pei, F., Li, W., & Wu, Y. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.11.015 · Cited by 125
Systems biology and its application to the understanding of neurological diseases
Villoslada, P., Steinman, L., & Baranzini, S. E. (2009) · Annals of Neurology · doi:10.1002/ana.21634 · Cited by 123
“20,84,85 For example, the in vivo transcriptional response to interferon-(cid:1) was recently studied using a network-based conceptual analysis.”
BackgroundA computational analysis of protein-protein interaction networks in neurodegenerative diseases
Goñi, J., Esteban, F. J., de Mendizábal, N. V., Sepulcre, J., Ardanza-Trevijano, S., Agirrezabal, I., & Villoslada, P. (2008) · BMC Systems Biology · doi:10.1186/1752-0509-2-52 · Cited by 121
“In addition, understanding the emergent properties of a system might help identify new targets that would not be captured by a molecular approach [8].”
Dunkel, P., Chai, C. L., Sperlágh, B., Huleatt, P. B., & Mátyus, P. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.703178 · Cited by 102
HSP90 inhibition: two-pronged exploitation of cancer dependencies
Travers, J., Sharp, S. Y., & Workman, P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.021 · Cited by 110
Khan, F. M., Marquardt, S., Gupta, S. K., Knoll, S., Schmitz, U., Spitschak, A., Engelmann, D., Vera, J., Wolkenhauer, O., & Pützer, B. M. (2017) · Nature Communications · doi:10.1038/s41467-017-00268-2 · Cited by 111
The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications
Kinnings, S., Xie, L., Fung, K. H., Jackson, R. M., Xie, L., & Bourne, P. E. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000976 · Cited by 109
“This is beneficial since multi-target therapy is thought to be more effective than single-target therapy when treating infectious diseases [77].”
BackgroundCalzaferri, F., Ruiz‐Ruiz, C., de Diego, A. M. G., de Pascual, R., Méndez‐López, I., Cano‐Abad, M. F., Maneu, V., de los Ríos, C., Gandía, L., & García, A. G. (2020) · Medicinal Research Reviews · doi:10.1002/med.21710 · Cited by 97
Chu, L., & Chen, B. (2008) · BMC Systems Biology · doi:10.1186/1752-0509-2-56 · Cited by 107
“From a systems biology perspective, cancer is mainly caused by malfunctions of perturbed protein interaction networks in the cell [5,6].”
BackgroundIkarashi, Y., & Mizoguchi, K. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.018 · Cited by 107
Xie, L., Xie, L., & Bourne, P. E. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp220 · Cited by 105
“It is believed that multi-target therapy is more effective than single-target therapy to treat parasitic diseases such as drug-resistant tuberculosis ( Kitano, 2007 ).”
BackgroundNetwork-Based Approaches in Drug Discovery and Early Development
Harrold, J. M., Ramanathan, M., & Mager, D. E. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.176 · Cited by 96
“60”
High‐order combination effects and biological robustness
Lehár, J., Krueger, A., Zimmermann, G., & Borisy, A. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.51 · Cited by 95
“metabolites, genes, proteins, or pathways) in a network that can selectively control the state of a biological system (Kitano, 2007; Kubinyi, 2003).”
A global view of drug-therapy interactions
Nacher, J. C., & Schwartz, J. (2008) · BMC Pharmacology · doi:10.1186/1471-2210-8-5 · Cited by 102
“In contrast, new findings suggest that multi-target drugs not only maximize the number of possible points of action but also introduce novel network disruption and systems-oriented strategies [12,13].”
BackgroundTRAIL therapy and prospective developments for cancer treatment
Thapa, B., Remant, K. C., & Uludağ, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.013 · Cited by 99
Kim, H. U., Kim, T. Y., & Lee, S. Y. (2009) · Molecular BioSystems · doi:10.1039/b916446d · Cited by 94
Molecular network of microRNA targets in Alzheimer's disease brains
Satoh, J. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.09.003 · Cited by 92
Nanoparticle-based combination drug delivery systems for synergistic cancer treatment
Choi, J. Y., Thapa, R. K., Yong, C. S., & Kim, J. O. (2016) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-016-0252-1 · Cited by 91
Hypoglycemic Effect of the Water Extract of Pu-erh Tea
Du, W.-H., Peng, S., Liu, Z., Shi, L., Tan, L., & Zou, X.-Q. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf302426w · Cited by 90
Network Systems Underlying Traditional Chinese Medicine Syndrome and Herb Formula
Li, S. (2009) · Current Bioinformatics · doi:10.2174/157489309789071129 · Cited by 87
“Thus, the multi-component therapeutics is believed to be more suitable to control the network-based complex disease or ZHENG, and the rich-experienced TCM Fu-Fang could serve as a huge resource of empirical multicomponent treatments and provide fertile ground for current systems-based drug development [71, 72].”
BackgroundBarkoulas, M., van Zon, J. S., Milloz, J., van Oudenaarden, A., & Félix, M. (2013) · Developmental Cell · doi:10.1016/j.devcel.2012.12.001 · Cited by 87
A framework for evolutionary systems biology
Loewe, L. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-27 · Cited by 87
P4 Medicine: the Future Around the Corner
Sobradillo, P., Pozo, F., & Agustí, A. G. N. (2011) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(11)70006-4 · Cited by 84
Huang, L., Jiang, Y., & Chen, Y. (2017) · Scientific Reports · doi:10.1038/srep40752 · Cited by 84
Exponential stability of genetic regulatory networks with random delays
Lou, X., Ye, Q., & Cui, B. (2009) · Neurocomputing · doi:10.1016/j.neucom.2009.10.006 · Cited by 83
Comprehensive analysis of human microRNA target networks
Satoh, J.-I., & Tabunoki, H. (2011) · BioData Mining · doi:10.1186/1756-0381-4-17 · Cited by 73
Systems Biology of Fungal Infection
Horn, F., Heinekamp, T., Kniemeyer, O., Pollmächer, J., Valiante, V., & Brakhage, A. A. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00108 · Cited by 73
“In the interests of clinical success, a system-oriented drug design with multiple antifungal strategies needs to affect sufficient points in the infection process (Kitano, 2007).”
BackgroundTheoretical and experimental analysis links isoform-specific ERK signalling to cell fate decisions
Schilling, M., Maiwald, T., Hengl, S., Winter, D., Kreutz, C., Kolch, W., Lehmann, W. D., Timmer, J., & Klingmüller, U. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.91 · Cited by 79
“We dissect the roles of the isoforms ERK1 and ERK2 and therefore provide an important basis for systems-oriented drug design (Kitano, 2007), opening new possibilities for interventions against cancer.”
BackgroundA systems approach to clinical oncology uses deep phenotyping to deliver personalized care
Yurkovich, J. T., Tian, Q., Price, N. D., & Hood, L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0273-6 · Cited by 79
Chronopharmaceutical drug delivery systems: Hurdles, hype or hope?☆
Youan, B.-B. C. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.010 · Cited by 79
“Overall, regardless of the methods and materials involved in the design of rhythmic biomaterials and systems, the concepts of robustness in controlling complex systems [29] and reversibility in response are critical for the future successful application of these biomaterials and systems in disease therapy and preventi…”
BackgroundWon, J., Yang, H. W., Shin, S., Lee, J., Heo, W. D., & Cho, K. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs021 · Cited by 79
“To quantify the effect of the MEK inhibitor, we investigated the area under curve (AUC) of the time trajectories of phospho-Akt and phospho-ERK after EGF stimulation and compared the percent change of AUC before and after the application of the MEK inhibitor.”
BackgroundMethodInfluentialVo, D. T., Abdelmohsen, K., Martindale, J. L., Qiao, M., Tominaga, K., Burton, T. L., Gelfond, J. A. L., Brenner, A. J., Patel, V., Trageser, D., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0208 · Cited by 76
Systematic prediction of drug combinations based on clinical side-effects
Huang, H., Zhang, P., Qu, X. A., Sanseau, P., & Yang, L. (2014) · Scientific Reports · doi:10.1038/srep07160 · Cited by 73
CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules
Lee, J. H., Kim, D. G., Bae, T., Rho, K., Kim, J. T., Lee, J.-J., Jang, Y., Kim, B. C., Park, K. M., & Kim, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042573 · Cited by 73
“Cancer cells possess compensatory mechanisms to overcome perturbations where they occur at one signalling axis and so therapies targeting only one pathway can fail in clinical trials due to lack of efficacy, or be overcome by mutations at an important receptor [4].”
BackgroundKim, T. Y., Kim, H. U., & Lee, S. Y. (2009) · Metabolic Engineering · doi:10.1016/j.ymben.2009.05.004 · Cited by 71
“In this regard, inhibition of the multienzyme targets identified by metabolite-centric approaches will be able to provide system-wide damage to the pathogen’s system (Hartwell et al., 1999; Kitano, 2007), assure cell lethality (Guimera et al.”
BackgroundCell Type–Specific Importance of Ras–c-Raf Complex Association Rate Constants for MAPK Signaling
Kiel, C., & Serrano, L. (2009) · Science Signaling · doi:10.1126/scisignal.2000397 · Cited by 66
“in the amount of the drug target protein will neutralize the effect of this drug (34).”
BackgroundZhang, Q., Zheng, D., Dong, X., Pan, P., Zeng, S.-M., Gao, F., Cheng, S., & Zhang, X. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00945 · Cited by 70
Topological network measures for drug repositioning
Badkas, A., Landtsheer, S. D., & Sauter, T. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa357 · Cited by 68
Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity
Ho, Ho, Sánchez, Shahangian, Al-Shyoukh, & Cheng (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s27540 · Cited by 67
Ji, H.-F., Kong, D.-X., Shen, L., Chen, L.-L., Ma, B.-G., & Zhang, H.-Y. (2007) · Genome Biology · doi:10.1186/gb-2007-8-8-r176 · Cited by 59
“One is called the multicomponent therapeutic strategy, which incorporates two or more active ingredients in one drug [86-89], as was applied in some traditional medicines (in China and many other countries) and in recently developed drug cocktails.”
BackgroundProtein Engineering: A New Frontier for Biological Therapeutics
Tobin, P., Richards, D., Callender, R., & Wilson, C. (2015) · Current Drug Metabolism · doi:10.2174/1389200216666141208151524 · Cited by 54
“It uses new quantitative methods to measure signaling network status, computational methods to model the signaling network, and multistage, multicomponent drug treatment programs based on measured network status and model predictions [122].”
Method
Metadata
- Authors
- Kitano, H.
- Affiliations
- Sony Computer Science Laboratories (JP)
- Corresponding author
- Kitano, Hiroaki
- ORCID
- Kitano, Hiroaki
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-02-23
- Volume
- 6
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1504533062
- Cited by
- 488
- References
- 105
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 9 · 2023: 6 · 2022: 15 · 2021: 8 · 2020: 18 · 2019: 20 · 2018: 16 · 2017: 25 · 2016: 29 · 2015: 37 · 2014: 30 · 2013: 32 · 2012: 47
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- robustness, biological robustness, complex networks, control theory, communication theory, cellular systems, drug efficacy, adverse drug reactions, systems biology
- MeSH terms
- Animals, Communicable Diseases, Pharmaceutical Preparations, Humans, Models, Theoretical, Neoplasms, Technology, Pharmaceutical, Drug Design, Signal Transduction, Cell Proliferation, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.